An observational study in HER2-positive Breast Cancer, sponsored by Hebei Medical University Fourth Hospital. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by Hebei Medical University Fourth Hospital · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Breast Neoplasms by Hebei Medical University Fourth Hospital — 12 open to participants now, 14 under way, 1 of them phase 3. Breast Neoplasms · Hebei Medical University Fourth Hospital.
Among the 22 studies in Breast Neoplasms by Hebei Medical University Fourth Hospital, this one is one of 3 that started in 2025, is one of 5 observational ones, reaches primary completion later than 13 of the 13 other live ones, and was the 16th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →12 of the 22 studies in Breast Neoplasms by Hebei Medical University Fourth Hospital are open now, in 1 country. Recruiting first, the newest first:
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–75 · Women only
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–65 · Women only
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–75 · Women only
Hebei Medical University Fourth Hospital · Sites in China
Ages 55+ · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 3 · Phase 4 2
First in 2015; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is close to the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 100 across the 17 interventional studies, 420 across the 5 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hebei Medical University Fourth Hospital is the lead sponsor of 81 studies on the registry; 54 are open to participants now.
6 of the studies in Breast Neoplasms by Hebei Medical University Fourth Hospital that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04290793Phase 3Hebei Medical University Fourth HospitalNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | 2026-12-01 |
| NCT06107673Hebei Medical University Fourth HospitalDalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC) | 2026-12-01 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
| NCT07492394Hebei Medical University Fourth HospitalDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | 2026-12-31 |
| NCT06973525Hebei Medical University Fourth HospitalThis Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 22 studies in Breast Neoplasms by Hebei Medical University Fourth Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neratinib is an oral, irreversible pan-HER tyrosine kinase inhibitor. Current treatment guidelines recommend neratinib as an extended adjuvant therapy for HER2-positive breast cancer patients to further reduce the risk of recurrence.
Even when HER2-positive breast cancer patients achieve pathological complete response (pCR) after neoadjuvant therapy, those with high-risk factors (such as large tumors [cT3/T4] or lymph node-positive disease) still face a risk of cancer returning. However, there is limited data on the effectiveness and safety of neratinib in these patients.
This study aims to provide real-world evidence on how well neratinib works in high-risk HER2-positive breast cancer patients who achieved pCR, helping to improve treatment strategies for Chinese patients.
This study is a single-arm prospective study with historical controls as external comparators
This study focuses on HER2-positive early breast cancer (EBC) patients who achieved pathological complete response (pCR) following neoadjuvant therapy but present with high-risk features (such as initial clinical stage cT3/T4 tumors or node-positive disease). These patients must have completed standard adjuvant therapy (including trastuzumab-based regimens) and initiated neratinib as extended adjuvant treatment within 6 months after completing their standard therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequential neratinib extended adjuvant therapy will be initiated within 6 months after completing standard trastuzumab-based adjuvant therapy, continuing for 1 year. As a real-world non-interventional study, treating physicians will determine neratinib regimens per the prescribing information and current clinical practice. Neratinib Dosing: Standard regimen: 240 mg (6 tablets) once daily with food for 1 year; Dose escalation (to mitigate diarrhea, per latest CSCO Breast Cancer Guidelines and FDA labeling): Week 1: 120 mg/day (days 1-7) Week 2: 160 mg/day (days 8-14) Week 3 onward: 240 mg/day (days 15-365)
Invasive Disease Free Survival (IDFS)
IDFS, as defined by the STEEP System, was measured from the date of treatment to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause.
Time frame: From Day 1 of treatment until 2 years after treatment completion
Disease Free Survival (DFS)
Disease-free survival is defined as the time from baseline until the first occurrence of DCIS or an iDFS event (an iDFS event including invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, or distant recurrence and death from any).
Time frame: From Day 1 of treatment until 2 years after treatment completion
Overall Survival (OS)
OS was defined as the time from baseline to death due to any cause, censored at the last date known alive.
Time frame: From Day 1 of treatment until 2 years after treatment completion
Distant Disease-free Survival (DDFS)
Distant disease-free survival time is defined as the time from baseline until the first occurrence of distant recurrence or death from any cause.
Time frame: From Day 1 of treatment until 2 years after treatment completion
Time to distant recurrence
defined as time from baseline to the date of the first distant recurrence or death from breast cancer
Time frame: From Day 1 of treatment until the first distant tumor recurrence or metastasis
Cumulative incidence of CNS recurrence
Time frame: From Day 1 of treatment until 2 years after treatment completion
Incidence of grade ≥3 diarrhea
Time frame: From consent to 28 days after last dose
Incidence and severity of other adverse events (AEs)
Time frame: From consent to 28 days after last dose
Treatment patterns of patients
Time frame: From Day 1 of treatment until last dose
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2025; primary completion for Jul 2029, 49 months later.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 49 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hebei Medical University Fourth Hospital